findmyKOL

Warren Paroly, MD

Basic profile

Dartmouth–Hitchcock Medical Center

ORCIDNone on fileNPI
RegionOceanside, CA · WestSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2010Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Warren Paroly is an Oncology physician affiliated with Dartmouth–Hitchcock Medical Center. OpenAlex indexes 6 publications with 460 citations (h-index 6).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
6publications

Distinct works indexed by OpenAlex.

460citations

Total citations across indexed works.

6h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
41companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3925 Waring Rd Ste C
Oceanside, CA 920564459

Telephone

760-758-5770

Registry record last updated 8 Jul 2007.

View the NPPES registry record

Industry payments

41 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    94.5%
    Erythropoiesis-stimulating Agent94.5%
    Darbepoetin alfa100%Retacrit0%
    Part D + Part B<11 patients
  • Musculoskeletal

    4.9%
    RANK Ligand Inhibitor4.9%
    Denosumab100%
    Part B, office-administered14 patients
  • Cancer & immunology

    0.4%
    Kinase inhibitor0.1%
    Imbruvica45%Brukinsa29%Calquence26%
    Part D<11 patients
    Aromatase Inhibitor0.1%
    Exemestane52%Letrozole48%
    Part D<11 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

1 more publication behind the reveal.Reveal →

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”